Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable

Author(s): Nidhi Aggarwal, Zufika Qamar, Saleha Rehman, Sanjula Baboota, Javed Ali*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 19 , 2020

Become EABM
Become Reviewer

Abstract:

As per the present global scenario, Parkinson’s disease (PD) is considered to be the second most common neurodegenerative disorder which is a keen area of interest among researchers. The conventional therapies generally employed against PD are associated with serious drawbacks including limited transport across selectively permeable BBB, hepatic metabolism, intestinal barrier, etc. This urges the need to develop novel therapeutic alternatives. The oral route being the most preferred route of administration needs to be explored for new and more intelligent drug delivery systems. Nanotechnology has been proposed to play a promising role in reversing the progression of the disease via the oral route. Nanocarriers, namely nanoparticles, lipid nanoparticles, nanoemulsions, nanocrystals, nanomicellar formulations, self-nanoemulsifying drug delivery systems and alginate nanocomposites have been investigated upon to modulate the fate of drugs inside the human body when administered orally. The development of various nanotherapeutics for the treatment of PD has been reviewed, depicting an enhanced bioavailability to provide a desired therapeutic outcome. The new advances in the therapy have been explored and highlighted through the body of this review. However, a therapeutically effective concentration at the target site remains a challenge, therefore extensive exploration in the field of nanotherapeutics may facilitate superior drug delivery to CNS via oral route thereby improving the state of disease progression.

Keywords: Parkinson's disease, oral administration, blood-brain barrier, nanoparticles, lipid nanoparticles, bioavailability.

[1]
Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and new hope 2017; 10(5): 499-502.
[http://dx.doi.org/10.1242/dmm.030205]
[2]
Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Mov Disord 2015; 30(11): 1442-50.
[http://dx.doi.org/10.1002/mds.26354] [PMID: 26208210]
[3]
Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8(12): 1150-7.
[http://dx.doi.org/10.1016/S1474-4422(09)70238-8] [PMID: 19909913]
[4]
Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9(1): 13-24.
[http://dx.doi.org/10.1038/nrneurol.2012.242] [PMID: 23183883]
[5]
Raza C, Anjum R, Shakeel NUA. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci 2019; 226: 77-90.
[http://dx.doi.org/10.1016/j.lfs.2019.03.057] [PMID: 30980848]
[6]
Hayes MT. Parkinson’s Disease and Parkinsonism. Am J Med 2019; 132(7): 802-7.
[http://dx.doi.org/10.1016/j.amjmed.2019.03.001] [PMID: 30890425]
[7]
Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India 2018; 66(7)(Suppl.): S26-35.
[http://dx.doi.org/10.4103/0028-3886.226451] [PMID: 29503325]
[8]
Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord 2011; 26(6): 1049-55.
[http://dx.doi.org/10.1002/mds.23732] [PMID: 21626550]
[9]
Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson’s disease research. Nat Rev Drug Discov 2011; 10(5): 377-93.
[http://dx.doi.org/10.1038/nrd3430] [PMID: 21532567]
[10]
Gunay MS, Ozer AY, Chalon S. SilindirGunay M. Yekta Ozer A, Chalon S. Drug delivery systems for imaging and therapy of Parkinson’s disease. Curr Neuropharmacol 2016; 14(4): 376-91.
[http://dx.doi.org/10.2174/1570159X14666151230124904] [PMID: 26714584]
[11]
Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004; 10(12): 1355-63.
[http://dx.doi.org/10.2174/1381612043384826] [PMID: 15134486]
[12]
Pardridge WM. Targeting neurotherapeutic agents through the blood-brain barrier. Arch Neurol 2002; 59(1): 35-40.
[http://dx.doi.org/10.1001/archneur.59.1.35] [PMID: 11790228]
[13]
Fischer NO, Weilhammer DR, Dunkle A, et al. Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One 2014; 9(3)e93342
[http://dx.doi.org/10.1371/journal.pone.0093342] [PMID: 24675794]
[14]
Hnatyszyn HJ, Kossovsky N, Gelman A, Sponsler E. Drug delivery systems for the future. PDA J Pharm Sci Technol 1994; 48(5): 247-54.
[PMID: 8000899]
[15]
Bhaskar S, Tian F, Stoeger T, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010; 7(1): 3.
[http://dx.doi.org/10.1186/1743-8977-7-3] [PMID: 20199661]
[16]
Saeedi M, Eslamifar M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother 2019; 111: 666-75.
[http://dx.doi.org/10.1016/j.biopha.2018.12.133] [PMID: 30611991]
[17]
Zhang F, Lin YA, Kannan S, Kannan RM. Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release 2016; 240: 212-26.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.013] [PMID: 26686078]
[18]
Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003; 2(4): 289-95.
[http://dx.doi.org/10.1038/nrd1067] [PMID: 12669028]
[19]
Banerjee A, Onyuksel H. Peptide delivery using phospholipid micelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4(5): 562-74.
[http://dx.doi.org/10.1002/wnan.1185] [PMID: 22847908]
[20]
McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 2010; 12(4): 461-70.
[PMID: 20677097]
[21]
Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013; 65(1): 315-499.
[http://dx.doi.org/10.1124/pr.112.005660] [PMID: 23383426]
[22]
Banerjee A, Lee J, Mitragotri S. Intestinal mucoadhesive devices for oral delivery of insulin. Bioeng Transl Med 2016; 1(3): 338-46.
[http://dx.doi.org/10.1002/btm2.10015] [PMID: 29313019]
[23]
Huang X, Xiao Y, Lang M. Micelles/sodium-alginate composite gel beads: A new matrix for oral drug delivery of indomethacin. Carbohydr Polym 2012; 87(1): 790-8.
[http://dx.doi.org/10.1016/j.carbpol.2011.08.067]
[24]
Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B 2013; 3(6): 361-72.
[http://dx.doi.org/10.1016/j.apsb.2013.10.001]
[25]
Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010; 62(11): 1622-36.
[http://dx.doi.org/10.1111/j.2042-7158.2010.01107.x] [PMID: 21039546]
[26]
Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharm Sci Technol Today 2000; 3(4): 138-45.
[http://dx.doi.org/10.1016/S1461-5347(00)00247-9] [PMID: 10754543]
[27]
Zhang J, Xie Z, Zhang N, Zhong J. Nanosuspension drug delivery system: preparation, characterization, postproduction processing, dosage form, and applicationNanostructures for Drug Delivery. Elsevier 2017; pp. 413-43.
[http://dx.doi.org/10.1016/B978-0-323-46143-6.00013-0]
[28]
Ganesan P, Ko HM, Kim IS, Choi DK. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models. Int J Nanomedicine 2015; 10: 6757-72.
[http://dx.doi.org/10.2147/IJN.S93918] [PMID: 26604750]
[29]
Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK. Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson’s Disease Models. Front Pharmacol 2019; 9: 1555.
[http://dx.doi.org/10.3389/fphar.2018.01555] [PMID: 30941047]
[30]
Wang Y, Wang S, Firempong CK, et al. Enhanced solubility and bioavailability of naringenin via liposomal nanoformulation: preparation and in vitro and in vivo evaluations. AAPS PharmSciTech 2017; 18(3): 586-94.
[http://dx.doi.org/10.1208/s12249-016-0537-8] [PMID: 27151135]
[31]
Siu FY, Ye S, Lin H, Li S. Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity. Int J Nanomedicine 2018; 13: 4133-44.
[http://dx.doi.org/10.2147/IJN.S164235] [PMID: 30038494]
[32]
Siddique YH, Khan W, Singh BR, Naqvi AH. Synthesis of alginate-curcumin nanocomposite and its protective role in transgenic Drosophila model of Parkinson’s disease. ISRN Pharmacol 2013; 2013794582
[http://dx.doi.org/10.1155/2013/794582] [PMID: 24171120]
[33]
Aluani D, Tzankova V, Kondeva-Burdina M, et al. Еvaluation of biocompatibility and antioxidant efficiency of chitosan-alginate nanoparticles loaded with quercetin. Int J Biol Macromol 2017; 103: 771-82.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.05.062] [PMID: 28536020]
[34]
Kuo YC, Rajesh R. Current development of nanocarrier delivery systems for Parkinson’s disease pharmacotherapy. Journal of the Taiwan Institute of Chemical Engineers 2018; 1-11.
[http://dx.doi.org/10.1016/j.jtice.2018.03.028]
[35]
Leyva-Gómez G, Cortés H, Magaña JJ, Leyva-García N, Quintanar-Guerrero D, Florán B. Nanoparticle technology for treatment of Parkinson’s disease: the role of surface phenomena in reaching the brain. Drug Discov Today 2015; 20(7): 824-37.
[http://dx.doi.org/10.1016/j.drudis.2015.02.009] [PMID: 25701281]
[36]
Gunay MS, Ozer AY, Chalon S. Drug delivery systems for imaging and therapy of Parkinson’s disease. Curr Neuropharmacol 2016; 14(4): 376-91.
[http://dx.doi.org/10.2174/1570159X14666151230124904] [PMID: 26714584]
[37]
Kang YS, Jung HJ, Oh JS, Song DY. Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood-Brain Barrier in a Rat Model of Parkinson’s Disease. CNS Neurosci Ther 2016; 22(10): 817-23.
[http://dx.doi.org/10.1111/cns.12580] [PMID: 27350533]
[38]
Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier. Pharmaceutics 2014; 6(4): 557-83.
[http://dx.doi.org/10.3390/pharmaceutics6040557] [PMID: 25407801]
[39]
Huang R, Ma H, Guo Y, et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson’s disease. Pharm Res 2013; 30(10): 2549-59.
[http://dx.doi.org/10.1007/s11095-013-1005-8] [PMID: 23703371]
[40]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Controled Release 2017; 264: 306-32.
[41]
Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018; 13(4): 288.
[42]
Kumar S, Dilbaghi N, Saharan R, Bhanjana G. Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. Bionanoscience 2012; 2(4): 227-50.
[43]
Krstić M, Medarević Đ, Đuriš J, Ibrić S. Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. Inlipid Nanocarriers Drug Target 2018 473 508.
[44]
Tanya M. SL KH. SMEDDS/SNEDDS: an emerging technique to solubility enhancement for the pharmaceutical industry. World J Pharm Pharm Sci 2017; 6(7): 317-36.
[45]
Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol 2018; 9(1): 1050-74.
[http://dx.doi.org/10.3762/bjnano.9.98] [PMID: 29719757]
[46]
Shin WK, Cho J, Kannan AG, Lee YS, Kim DW. Cross-linked composite gel polymer electrolyte using mesoporous methacrylate-functionalized SiO 2 nanoparticles for lithium-ion polymer batteries. Sci Rep 2016; 6: 26332.
[http://dx.doi.org/10.1038/srep26332] [PMID: 27189842]
[47]
Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications, and toxicities. Arab J Chem 2019; 12(7): 908-31.
[http://dx.doi.org/10.1016/j.arabjc.2017.05.011]
[48]
Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. J Appl Pharm Sci 2011; 1(6): 228-34.
[49]
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016; 235: 34-47.
[http://dx.doi.org/10.1016/j.jconrel.2016.05.044] [PMID: 27208862]
[50]
Ngwuluka NC, Ochekpe NA, Aruoma OI. Naturapolyceutics: the science of utilizing natural polymers for drug delivery. polymers 2014; 6(5): 1312-32.
[51]
Kundu P, Das M, Tripathy K, Sahoo SK. Delivery of dual drug loaded lipid-based nanoparticles across the blood–brain barrier imparts enhanced neuroprotection in a rotenone induced mouse model of Parkinson’s disease. ACS Chem Neurosci 2016; 7(12): 1658-70.
[http://dx.doi.org/10.1021/acschemneuro.6b00207] [PMID: 27642670]
[52]
Bhatt D, Ajmeri N, Mandal S, Nanoparticle KSR. design, characterization and evaluation for oral delivery of ropinirole hydrochloride. Elixir Pharmacy 2011; 39: 4687-9.
[53]
Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 2008; 128(3): 185-99.
[http://dx.doi.org/10.1016/j.jconrel.2008.02.007] [PMID: 18374443]
[54]
Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011; 8(11): 1407-24.
[http://dx.doi.org/10.1517/17425247.2011.604311] [PMID: 21831007]
[55]
Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34(12): 1394-405.
[http://dx.doi.org/10.1080/03639040802130061] [PMID: 18665980]
[56]
Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010; 27(8): 1469-86.
[http://dx.doi.org/10.1007/s11095-010-0130-x] [PMID: 20411409]
[57]
Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012; 9(5): 497-508.
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[58]
Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014; 86(1): 7-22.
[http://dx.doi.org/10.1016/j.ejpb.2013.08.013] [PMID: 24007657]
[59]
Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 2014; 87(3): 433-44.
[http://dx.doi.org/10.1016/j.ejpb.2014.05.004] [PMID: 24833004]
[60]
O’Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. Adv Drug Deliv Rev 2008; 60(6): 617-24.
[http://dx.doi.org/10.1016/j.addr.2007.10.012] [PMID: 18155800]
[61]
Daeihamed M, Dadashzadeh S, Haeri A, Akhlaghi MF. Potential of liposomes for enhancement of oral drug absorption. Curr Drug Deliv 2017; 14(2): 289-303.
[PMID: 26768542]
[62]
Wang Y, Xu H, Fu Q, Ma R, Xiang J. Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J Neurol Sci 2011; 304(1-2): 29-34.
[http://dx.doi.org/10.1016/j.jns.2011.02.025] [PMID: 21376343]
[63]
Bargoni A, Cavalli R, Caputo O, Fundarò A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998; 15(5): 745-50.
[http://dx.doi.org/10.1023/A:1011975120776] [PMID: 9619784]
[64]
Ganesan P, Ramalingam P, Karthivashan G, Ko YT, Choi DK. Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases. Int J Nanomedicine 2018; 13: 1569-83.
[http://dx.doi.org/10.2147/IJN.S155593] [PMID: 29588585]
[65]
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50(1): 161-77.
[http://dx.doi.org/10.1016/S0939-6411(00)00087-4] [PMID: 10840199]
[66]
Siekmann B, Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992; 1(3): 123-6.
[67]
Mehta RC, Head LF, Hazrati AM, Parr M, Rapp RP, DeLuca PP. Fat emulsion particle-size distribution in total nutrient admixtures. Am J Hosp Pharm 1992; 49(11): 2749-55.
[http://dx.doi.org/10.1093/ajhp/49.11.2749] [PMID: 1471641]
[68]
Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 2011; 100(2): 547-57.
[http://dx.doi.org/10.1002/jps.22285] [PMID: 20740670]
[69]
Patil D, Pattewar S, Palival S, Patil G, Sharma S. Nanostructured lipid carriers: A platform to a lipophilic drug for oral bioavailability enhancement. J Drug Deliv Ther 2019; 9(3-s): 758-64.
[70]
Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA 2016; 2(3)FSO135
[http://dx.doi.org/10.4155/fsoa-2016-0030] [PMID: 28031979]
[71]
Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine (Lond) 2014; 10(4): 755-64.
[http://dx.doi.org/10.1016/j.nano.2013.10.009] [PMID: 24200526]
[72]
Aboalnaja KO, Yaghmoor S, Kumosani TA, McClements DJ. Utilization of nanoemulsions to enhance bioactivity of pharmaceuticals, supplements, and nutraceuticals: Nanoemulsion delivery systems and nanoemulsion excipient systems. Expert Opin Drug Deliv 2016; 13(9): 1327-36.
[http://dx.doi.org/10.1517/17425247.2016.1162154] [PMID: 26984045]
[73]
Shinde RL, Jindal AB, Devaranjan PV. Microemulsion and Nanoemulsions for Targeted Drug Delivery to the Brain. Curr Nanosci 2011; 7(1): 119-33.
[http://dx.doi.org/10.2174/157341311794480282]
[74]
Kotta S, Khan AW, Pramod K, Ansari SH, Sharma RK, Ali J. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 2012; 9(5): 585-98.
[http://dx.doi.org/10.1517/17425247.2012.668523] [PMID: 22512597]
[75]
Herneisey M, Williams J, Mirtic J, et al. Development and characterization of resveratrol nanoemulsions carrying dual-imaging agents. Ther Deliv 2016; 7(12): 795-808.
[http://dx.doi.org/10.4155/tde-2016-0050] [PMID: 27834615]
[76]
Singh Y, Meher JG, Raval K, et al. Nanoemulsion: Concepts, development and applications in drug delivery. J Control Release 2017; 252: 28-49.
[http://dx.doi.org/10.1016/j.jconrel.2017.03.008] [PMID: 28279798]
[77]
Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol 2010; 27(7): 260-73.
[http://dx.doi.org/10.3109/09687688.2010.497971] [PMID: 20929336]
[78]
Gupta BK, Kumar S, Kaur H, Ali J, Baboota S. Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson’s Disease. Rejuvenation Res 2018; 21(3): 232-48.
[http://dx.doi.org/10.1089/rej.2017.1959] [PMID: 28844183]
[79]
Sa F, Guo AJ, Li S, et al. Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A. Parkinsons Disease 2015.
[http://dx.doi.org/10.1155/2015/951361]
[80]
Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress. Nanotechnology 2014; 25(48)485102
[http://dx.doi.org/10.1088/0957-4484/25/48/485102] [PMID: 25392203]
[81]
Mohammad IS, Hu H, Yin L, He W. Drug nanocrystals: Fabrication methods and promising therapeutic applications. Int J Pharm 2019; 562: 187-202.
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.045] [PMID: 30851386]
[82]
Zhou Y, Du J, Wang L, Wang Y. Nanocrystal technology for improving the bioavailability of poorly soluble drugs: A mini-review. J Nanosci Nanotechnol 2017; 17(1): 18-28.
[http://dx.doi.org/10.1166/jnn.2017.13108] [PMID: 29616786]
[83]
Ren X, Qi J, Wu W, Yin Z, Li T, Lu Y. Development of carrier-free nanocrystals of poorly water-soluble drugs by exploring metastable zone of nucleation. Acta Pharm Sin B 2019; 9(1): 118-27.
[http://dx.doi.org/10.1016/j.apsb.2018.05.004] [PMID: 30766783]
[84]
Jarvis M, Krishnan V, Mitragotri S. Nanocrystals: A perspective on translational research and clinical studies. Bioeng Transl Med 2018; 4(1): 5-16.
[http://dx.doi.org/10.1002/btm2.10122] [PMID: 30680314]
[85]
Peltonen L, Strachan C. Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery. Molecules 2015; 20(12): 22286-300.
[http://dx.doi.org/10.3390/molecules201219851] [PMID: 26703528]
[86]
Chen C, Wang L, Cao F, et al. Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery. Int J Pharm 2016; 497(1-2): 239-47.
[http://dx.doi.org/10.1016/j.ijpharm.2015.12.014] [PMID: 26680316]
[87]
Fernandes AR, Dias-Ferreira J, Ferreira-da-Silva C, et al. Drug nanocrystals: present, past and future.Applications of Nanocomposite Materials in Drug Delivery. Woodhead Publishing Series in Biomaterials 2018 pp; 239-53.
[http://dx.doi.org/10.1016/B978-0-12-813741-3.00011-X]
[88]
Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release 2014; 183: 51-66.
[http://dx.doi.org/10.1016/j.jconrel.2014.03.030] [PMID: 24667572]
[89]
Gao L, Liu G, Ma J, et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res 2013; 30(2): 307-24.
[http://dx.doi.org/10.1007/s11095-012-0889-z] [PMID: 23073665]
[90]
Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: In vivo performances. J Control Release 2012; 160(3): 418-30.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.013] [PMID: 22465393]
[91]
Xiong S, Liu W, Zhou Y, et al. Enhancement of oral bioavailability and anti-parkinsonian efficacy of resveratrol through a nanocrystal formulation. Asian Journal of Pharmaceutics 2019; 16: 50.
[92]
Xiong S, Liu W, Li D, et al. Oral delivery of Puerarin nanocrystals to improve brain accumulation and anti-parkinsonian efficacy. Mol Pharm 2019; 16(4): 1444-55.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b01012] [PMID: 30811206]
[93]
Chen T, Li C, Li Y, Yi X, Lee SMY, Zheng Y. Oral Delivery of a Nanocrystal Formulation of Schisantherin A with Improved Bioavailability and Brain Delivery for the Treatment of Parkinson’s Disease. Mol Pharm 2016; 13(11): 3864-75.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00644] [PMID: 27740776]
[94]
Borowy-Borowski H, Sodja C, Docherty J, Walker PR, Sikorska M. Unique technology for solubilization and delivery of highly lipophilic bioactive molecules. J Drug Target 2004; 12(7): 415-24.
[http://dx.doi.org/10.1080/10611860412331285233] [PMID: 15621666]
[95]
Sikorska M, Lanthier P, Miller H, et al. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson’s disease. Neurobiol Aging 2014; 35(10): 2329-46.
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.03.032] [PMID: 24775711]
[96]
Soni GC, Prajapati SK, Chaudhari N. Self nanoemulsion: Advance form of drug delivery system. World J Pharm Pharm Sci 2014; 3(10): 410-36.
[97]
Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (Lond) 2010; 5(10): 1595-616.
[http://dx.doi.org/10.2217/nnm.10.126] [PMID: 21143036]
[98]
Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29(3-4): 278-87.
[http://dx.doi.org/10.1016/j.ejps.2006.04.016] [PMID: 16815001]
[99]
Wang L, Dong J, Chen J, Eastoe J, Li X. Design and optimization of a new self-nanoemulsifying drug delivery system. J Colloid Interface Sci 2009; 330(2): 443-8.
[http://dx.doi.org/10.1016/j.jcis.2008.10.077] [PMID: 19038395]
[100]
Rao SV, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm 2008; 362(1-2): 2-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.018] [PMID: 18650038]
[101]
Hussein ZA, Rajab NA. Formulation and Characterization of Bromocriptine Mesylate as Liquid Self-Nano Emulsifying Drug Delivery System. Iraqi J Pharm Sci 2018; 27(2): 93-101.
[http://dx.doi.org/10.31351/vol27iss2pp93-101]
[102]
Agrawal AG, Kumar A, Gide PS. Formulation development and in vivo hepatoprotective activity of self nanoemulsifying drug delivery system of antioxidant coenzyme Q10. Arch Pharm Res 2014; 1-16 In press..
[http://dx.doi.org/10.1007/s12272-014-0497-z] [PMID: 25503273]
[103]
Kunwar A, Priyadarshini KI. Free radicals, oxidative stress and importance of antioxidants in human health J. Med Allied Sci 2011; 1: 53-60.
[104]
Sharma S, Narang JK, Ali J, Baboota S. Synergistic antioxidant action of vitamin E and rutin SNEDDS in ameliorating oxidative stress in a Parkinson’s disease model. Nanotechnology 2016; 27(37:)375101.
[http://dx.doi.org/10.1088/0957-4484/27/37/375101] [PMID: 27491690]
[105]
Amin MM, El Gazayerly ON, Abd El-Gawad NA, Abd El-Halim SM, El-Awdan SA. Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats. Pharm Dev Technol 2016; 21(8): 909-20.
[http://dx.doi.org/10.3109/10837450.2015.1078354] [PMID: 26334707]
[106]
Rao SV, Agarwal P, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int J Pharm 2008; 362(1-2): 10-5.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.016] [PMID: 18640797]
[107]
Khanam S, Naz F, Ali F, et al. Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson’s disease. Toxicol Mech Methods 2018.
[http://dx.doi.org/10.1080/15376516.2018.1502386]
[108]
Giordano C, Albani D, Gloria A, et al. Nanocomposites for neurodegenerative diseases: hydrogel-nanoparticle combinations for a challenging drug delivery. Int J Artif Organs 2011; 34(12): 1115-27.
[http://dx.doi.org/10.5301/ijao.2011.8915] [PMID: 22198597]
[109]
Siddique YH, Khan W, Fatima A, et al. Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson’s disease. Dis Model Mech 2016; 9(1): 63-8.
[http://dx.doi.org/10.1242/dmm.022145] [PMID: 26542705]
[110]
1P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease (REPAIR-PD). NIH U.S. National Library of Medicine. Available at: www.clinicalTrials.gov
[111]
Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson's Disease with the Nanocatalytic Therapeutic, CNM-Au8. Clene nanomedicine, Inc. Available at: https://www.prnewswire.com/news-releases/clene-nanomedicine-presents-new-neuroprotection-data-in-parkinsons-disease-with-lead-nanocatalytic-therapeutic-cnm-au8-300944253.html


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 19
Year: 2020
Page: [2280 - 2290]
Pages: 11
DOI: 10.2174/1381612826666200406072451
Price: $65

Article Metrics

PDF: 13
HTML: 1